Results of Coronary Artery Bypass Grafting in Obese Patients

This study is planned to assess the effect of obesity (BMI over 30 kg / m2) on hospital outcomes of isolated coronary artery bypass grafting in patients with chronic ischemic heart disease.

Study Overview

Status

Completed

Detailed Description

This study is planned to assess the effect of obesity (BMI over 30 kg / m2) on hospital outcomes of isolated coronary artery bypass grafting in patients with chronic ischemic heart disease.

It is planned to retrospectively enroll around 500 patients who underwent coronary artery bypass grafting for chronic ischemic heart disease at the Tomsk Research Institute of Cardiology. It is planned to develop a register of isolated coronary bypass grafting procedures, to conduct a comparative analysis of hospital results in obese patients (BMI more than 30 kg / m2) and without (BMI less than 30 kg / m2), to identify risk factors for adverse outcomes in patients of this group of patients.

Planning methods:

  1. Clinical status of the patient: collection of complaints, medical history, physical examination, assessment of anthropometric indicators (measurement of body weight, height, BMI), and demographic indicators before and in the control period after surgical treatment.
  2. General clinical examination: standard 12-lead ECG, general urine analysis, general blood analysis, blood chemistry, coagulation, chest x-ray, ultrasound of the carotid and femoral arteries.
  3. Coronarography to assess the anatomy and condition of the coronary arteries.
  4. Echocardiography to assess the following parameters: mass of viable left ventricular myocardium; volumes of cardiac cavities; diameter of the mitral and tricuspid valve rings with the determination of regurgitation degree; the long axis of the ventricle; left ventricular ejection fraction; visualization of akinetic and hypokinetic myocardium; the presence of blood clots in the cavities of the heart; All surgical procedures will be performed via median sternotomy Intraoperative information will be collected from the anesthetic record, surgical notes and perfusion records. Intraoperative data collection will include total operative time, CPB time, cross-clamp time, intraoperative red blood cell transfusion (units), highest dose/agent used for intraoperative inotrope or vasopressor support. Intraoperative flowmetry of coronary grafts during coronary artery bypass grafting using the Medistim VeriQ System will be performed.

Postoperative data will include valuation of following indicators: mortality (hospital mortality and death from any cause); neurological injury (TIA, stroke, delirium), acute kidney injury (creatinine level prior and 1 postoperative day, urine output-up to 24-48 h, renal replacement therapy (dialysis); time of mechanical ventilation; re-exploration for bleeding, tamponade or other reasons; postoperative transfusion (packed red blood cells, platelets, fresh frozen platelets, cryoprecipitate); postoperative myocardial infarction (electrocardiogram and troponins); inotropic support during 24-48 h (agent and dose (VIS)); length of stay (intensive care unit and total hospital days).

Structured collection of patient data will be performed in a database formed on the platform of the Microsoft Excel 2010 software (Microsoft Corp., USA). Statistical processing of the results will be carried out using the SPSS 23.0 for Windows software package (IBM Corp., Armonk, NY, USA). The normality of the law of distribution of quantitative indicators will be checked using the Shapiro-Wilks criterion. Normally distributed parameters will be presented as mean value (M) and standard deviation (StD) in the form M ± StD; not normally distributed parameters will be presented as median (Me) and the 1st and 3rd interquantile intervals (Q25 - Q75) in the form of Me [Q25; Q75]. Qualitative data will be described by the frequency of occurrence or its percentage. To find statistical dependences, to determine their strength and direction, the Pearson correlation coefficient (r) (for normally distributed parameters) and Spearman correlation coefficient (for for not normally distributed parameters and for qualitative indicators in the ordinal scale) will be calculated. Using logistic regression, significant predictors will be identified for the values of reverse remodeling in the long term after surgical treatment. When conducting a multivariate analysis of interconnections, first, by means of a univariate analysis, the main parameters that influence the studied value will be identified, then, based on the search for intergroup correlations, the signs that have a moderate or strong relationship will be eliminated, and multivariate modeling of the relationships will be performed.

During the work, the methods of statistical analysis can be revised and (or) supplemented.

Study Type

Observational

Enrollment (Actual)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Tomsk State
      • Tomsk, Tomsk State, Russian Federation, 634012
        • Andrey Pryakhin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients being living in Russian Federation (inc. ethnic minorities) with chronic ischemic heart disease and indications for cardiac surgery

Description

Inclusion Criteria:

  • Clinical diagnosis of chronic ischemic heart disease
  • Indications for cardiac surgery
  • Stenosis of more than 75% of the trunk of the left coronary artery, or proximal stenosis of the anterior descending artery and/or stenosis of more than 75% of two or more coronary arteries

Exclusion Criteria:

  • The presence of organic heart defects of rheumatic and infectious etiology;
  • Acute myocardial infarction;
  • Less than 3 months after acute coronary or cerebrovascular events;
  • Severe pulmonary hypertension not associated with mitral regurgitation (above 75 mmHg);
  • Contraindications for operations with cardiopulmonary bypass;
  • Severe course of bronchial asthma,
  • Chronic obstructive pulmonary disease in the acute stage;
  • Refusal of the patient or relatives to participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
CABG-1
A group of non-obese patients (BMI less than 30 kg / m2) who underwent isolated coronary artery bypass grafting for chronic ischemic heart disease
Coronary artery bypass surgery is a surgical procedure to restore normal blood flow to an obstructed or stenotic coronary artery.
Other Names:
  • CABG
CABG-2
A group of obese patients (BMI over 30 kg / m2) who underwent isolated coronary artery bypass grafting for chronic ischemic heart disease
Coronary artery bypass surgery is a surgical procedure to restore normal blood flow to an obstructed or stenotic coronary artery.
Other Names:
  • CABG

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Death
Time Frame: 30 days
In-hospital mortality rate (%)
30 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
neurological injury
Time Frame: 30 days
neurological injury (TIA, stroke, delirium)
30 days
acute kidney injury
Time Frame: 30 days
creatinine level prior and 1 postoperative day, urine output-up to 24-48 h, renal replacement therapy
30 days
Duration of mechanical ventilation
Time Frame: 30 days
Duration of mechanical ventilation
30 days
re-exploration
Time Frame: 30 days
re-exploration for bleeding, tamponade or other reasons
30 days
postoperative transfusion
Time Frame: 30 days
packed red blood cells, platelets, fresh frozen platelets, cryoprecipitate
30 days
postoperative myocardial infarction
Time Frame: 30 days
postoperative myocardial infarction (electrocardiogram and troponins)
30 days
Duration of inotropic support
Time Frame: 48 hours
inotropic support during 24-48 h postoperatively
48 hours
length of stay
Time Frame: 30 days
length of stay (intensive care unit and total hospital days).
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Andrey S Pryakhin, PhD, Tomsk NRMC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2020

Primary Completion (Actual)

September 1, 2021

Study Completion (Actual)

September 1, 2022

Study Registration Dates

First Submitted

June 1, 2021

First Submitted That Met QC Criteria

June 1, 2021

First Posted (Actual)

June 8, 2021

Study Record Updates

Last Update Posted (Actual)

November 1, 2022

Last Update Submitted That Met QC Criteria

October 31, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on coronary artery bypass grafting

Subscribe